Table 2.
CCM and other measures of neuropathy in control subjects and patients with type 1 and type 2 diabetes
| Parameters | Control subjects (n = 72) | Type 2 diabetes (n = 269) | Type 1 diabetes (n = 149) | ANCOVA P value |
|---|---|---|---|---|
| CNFD (number/mm2) | 34.06 ± 0.95 | 25.98 ± 0.51* | 22.37 ± 0.67*$ | <0.0001 |
| CNBD (number/mm2) | 83.39 ± 4.39 | 63.22 ± 2.36* | 47.13 ± 3.11*$ | <0.0001 |
| CNFL (mm/mm2) | 24.76 ± 0.84 | 22.46 ± 0.45* | 17.84 ± 0.59*$ | <0.0001 |
| IENFD (number/mm) | 8.60 ± 0.85 | 6.85 ± 0.7 | 5.46 ± 0.56* | 0.007 |
| NDS (0–10) | 1.37 ± 0.32 | 3.13 ± 0.17* | 4.29 ± 0.22*$ | <0.0001 |
| NSP (0–38) | 0.8 ± 0.6 | 4.9 ± 0.5* | 5.3 ± 0.4* | <0.0001 |
| DB-HRV (bpm) | 25.96 ± 1.75 | 20.56 ± 1.05* | 21.75 ± 1.03* | 0.04 |
| VPT (V) | 9.85 ± 1.14 | 13.77 ± 0.61* | 18.98 ± 0.8*$ | <0.0001 |
| CPT (°C) | 27.45 ± 0.6 | 26.05 ± 0.34 | 23.47 ± 0.46*$ | <0.0001 |
| WPT (°C) | 38.00 ± 0.47 | 40.57 ± 0.25* | 41.23 ± 0.34* | <0.0001 |
| CIP (°C) | 10.69 ± 0.89 | 5.9 ± 0.66* | 7.06 ± 0.75* | <0.0001 |
| WIP (°C) | 45.22 ± 0.3 | 47.6 ± 0.22* | 46.82 ± 0.25*$ | <0.0001 |
| SNCV (m/s) | 48.82 ± 0.77 | 45.60 ± 0.41* | 39.26 ± 0.54*$ | <0.0001 |
| SNAP (μV) | 17.16 ± 0.81 | 10.86 ± 0.43* | 6.35 ± 0.57*$ | <0.0001 |
| PMNCV (m/s) | 46.89 ± 0.78 | 44.07 ± 0.41* | 38.22 ± 0.55*$ | <0.0001 |
| PMNA (mV) | 4.44 ± 0.27 | 3.86 ± 0.14 | 2.76 ± 0.19*$ | <0.0001 |
Data are mean ± SEM corrected for age using ANCOVA (least significant difference correction). All symbols represent statistically significant differences.
bpm, beats per minute.
*
Significant difference compared with control subjects.
$Significant difference compared with type 2 diabetes.